Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Ochoa, M.C. (María Carmen) | - |
dc.creator | Perez-Ruiz, E. (Elisabeth) | - |
dc.creator | Minute, L. (Luna) | - |
dc.creator | Oñate, C. (Carmen) | - |
dc.creator | Perez, G. (Guiomar) | - |
dc.creator | Rodriguez, I. (Inmaculada) | - |
dc.creator | Zabaleta, A. (Aintzane) | - |
dc.creator | Alignani, D. (Diego) | - |
dc.creator | Fernández-Sendín, M. (Myriam) | - |
dc.creator | Lopez, A. (Ascensión) | - |
dc.creator | Muntasell, A. (Aura) | - |
dc.creator | Fernandez-Sanmamed, M. (Miguel) | - |
dc.creator | Paiva, B. (Bruno) | - |
dc.creator | López-Botet, M. (Miguel) | - |
dc.creator | Berraondo, P. (Pedro) | - |
dc.creator | Melero, I. (Ignacio) | - |
dc.date.accessioned | 2021-09-20T08:02:05Z | - |
dc.date.available | 2021-09-20T08:02:05Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Ochoa, M.C. (María Carmen); Perez-Ruiz, E. (Elisabeth); Minute, L. (Luna); et al. "Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocytedeficient mice reconstituted with human NK cells". OncoImmunology. 8 (7), 2019, e1599636 | es_ES |
dc.identifier.issn | 2162-4011 | - |
dc.identifier.other | PMID: 31143521 | - |
dc.identifier.uri | https://hdl.handle.net/10171/62014 | - |
dc.description.abstract | Daratumumab is an anti-CD38 fully human IgG1 mAb approved for multiple myeloma treatment. One of the proposed mechanisms of action is the induction of antibody-dependent cellular cytotoxicity (ADCC) mediated by NK cells. NK cells acquire surface CD137 expression in the presence of solid-phase-attached daratumumab and when encountering a daratumumab-coated CD38+ tumor cell line. In this setting, addition of the agonist anti-CD137 mAb urelumab enhances NK-cell activation increasing CD25 expression and IFNɣ production. However, in vitro ADCC is not increased by the addition of urelumab both in 4h or 24h lasting experiments. To study urelumab-increased daratumumab-mediated ADCC activity in vivo, we set up a mouse model based on the intravenous administration of a luciferase-transfected multiple myeloma cell line of human origin, human NK cells and daratumumab to immuno-deficient NSG mice. In this model, intravenous administration of urelumab 24h after daratumumab delayed tumor growth and prolonged mice survival. | es_ES |
dc.description.sponsorship | This work was supported by Asociación Española contra el Cancer (Fundación AECC), Foundation for Applied Medical Research (FIMA), Worldwide Cancer Research (AIRC) and Fondo de Investigación Sanitaria-Fondo Europeo de Desarrollo Regional (FEDER) under Grant [PI16/00668]. This project has received funding from the European Union´s Horizon 2020 research and innovation programme (grant agreement [n° 635122 – PROCROP]. P.B. was supported by a Miguel Servet II [CPII15/00004] contract from Instituto de Salud Carlos III; | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Informa UK Limited | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Materias Investigacion::Ciencias de la Salud::Inmunología | es_ES |
dc.subject | NK cells | es_ES |
dc.subject | ADCC | es_ES |
dc.subject | Multiple myeloma | es_ES |
dc.subject | CD137 | es_ES |
dc.subject | Daratumumab | es_ES |
dc.title | Daratumumab in combination with urelumab to potentiate anti-myeloma activity in lymphocytedeficient mice reconstituted with human NK cells | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | cc-by | es_ES |
dc.identifier.doi | 10.1080/2162402x.2019.1599636 | - |
dadun.citation.number | 7 | es_ES |
dadun.citation.publicationName | OncoImmunology | es_ES |
dadun.citation.startingPage | e1599636 | es_ES |
dadun.citation.volume | 8 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.